Device manufacturer Medtronic has received U.S. Food and Drug Administration (FDA) approval for its quadripolar cardiac resynchronization therapy pacemakers (CRT-Ps) for heart failure patients.
The clearance covers Medtronic's Percepta Quad CRT-P MRI SureScan, Serena Quad CRT-P MRI SureScan, and Solara Quad CRT-P MRI SureScan pacemakers, which can be used in patients who undergo 1.5- or 3-tesla MRI scans.
Medtronic expects the pacemakers to be commercially available in the U.S. early in the quarter.
